Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Previous findings on the association of statins, plasma lipids, and Parkinson's disease (PD) are confounded by the fact that statins also affect lipid profiles. We prospectively examined plasma lipids and statin use in relation to PD in the Atherosclerosis Risk in Communities (ARIC) Study. Statin use and plasma lipids were assessed at baseline (visit 1, 1987‐89) and at three triennial visits thereafter (visits 2‐4) until 1998. Potential PD cases were identified from multiple sources and validated where possible. The primary analysis was limited to incident PD cases diagnosed between 1998 and 2008. Odds ratios and 95% confidence intervals were derived from multivariate logistic regression models. Statin use was rare at baseline (0.57%) but increased to 11.2% at visit 4. During this time frame, total‐cholesterol levels decreased, particularly among statin users. Fifty‐six PD cases were identified after 1998. Statin use before 1998 was associated with significantly higher PD risk after 1998 (odds ratio = 2.39, 95% confidence interval 1.11‐5.13) after adjusting for total cholesterol and other confounders. Conversely, higher total cholesterol was associated with lower risk for PD after adjustment for statin usage and confounders. Compared with the lowest tertile of average total cholesterol, the odds ratios for PD were 0.56 (0.30‐1.04) for the second and 0.43 (0.22‐0.87) for the third tertile (Ptrend = 0.02). Statin use may be associated with a higher PD risk, whereas higher total cholesterol may be associated with lower risk. These data are inconsistent with the hypothesis that statins are protective against PD. © 2015 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Cholesterol metabolism in neurons and astrocytes
Pfrieger, F. W., & Ungerer, N. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.06.002 · Cited by 500
Determinants of plasma coenzyme Q10 in humans
Kaikkonen, J., Nyyssönen, K., Tuomainen, T.-P., Ristonmaa, U., & Salonen, J. T. (1999) · FEBS Letters · doi:10.1016/s0014-5793(98)01712-8 · Cited by 97 · cited 2×
“Alternatively, high plasma cholesterol could merely be a marker of potential neuroprotective substrates such as coenzyme Q10.”
BackgroundResearch on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications
Chen, H., Burton, E. A., Ross, G. W., Huang, X., Savica, R., Abbott, R. D., Ascherio, A., Caviness, J. N., Gao, X., Gray, K. A., et al. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1306967 · Cited by 83 · cited 1×
“Parkinson’s disease is, however, increasingly recognized as a systemic disease that may start in the periphery such as the gut.(28) Thus, higher plasma cholesterol may be protective in early PD development via peripheral mechanisms.”
BackgroundSelf-citation
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Epidemiology of Parkinson's disease
Elbaz, A., Carcaillon, L., Kab, S., & Moisan, F. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 445
The Concept of Prodromal Parkinson’s Disease
Mahlknecht, P., Seppi, K., & Poewe, W. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150685 · Cited by 288
Mitochondrial Quality Control as a Therapeutic Target
Suliman, H. B., & Piantadosi, C. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011502 · Cited by 264
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178
Metadata
- Authors
- Huang, X., Alonso, A., Guo, X., Umbach, D. M., Lichtenstein, M. L., Ballantyne, C. M., Mailman, R. B., Mosley, T. H., & Chen, H.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2015-01-14
- Volume
- 30
- Issue
- 4
- Pages
- 552-559
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2150983672
- Cited by
- 142
- References
- 4
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study. https://app.cochat.ai/papers/10.1002/mds.26152
- The paper
- Huang, X., Alonso, A., Guo, X., Umbach, D. M., Lichtenstein, M. L., Ballantyne, C. M., Mailman, R. B., Mosley, T. H., & Chen, H. (2015). Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study. Movement Disorders. https://doi.org/10.1002/mds.26152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.